Goodwin Biotechnology, Inc. (GBI) and Rafagen, Inc. have entered a collaboration agreement for cell line engineering and biological contract manufacturing. Terms of the agreement were not disclosed. “We seek to address unmet needs of patients with inherited and acquired diseases,” said Sung Ho Hahm, Ph.D., co-founder, president and chief executive officer of Rafagen. “With Rafagen’s proprietary technology platforms, the highest producing cell lines will be established ...